Professor John Hardy (UCL Institute of Neurology) described AstraZeneca's reduction of its UK headcount as "a terrible blow to the UK pharmaceutical industry" born of the company's short-termism and "a hostile regulatory climate towards animal - especially rodent - work".
Read: THE
Close
